









Markets
/
Stocks
/
nasdaq-rgen
/

Repligen Corp

RGEN

142.180USD

+2.520+1.80%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.00BMarket Cap

5096.06P/E TTM



Repligen Corp

142.180

+2.520+1.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Repligen Corp

Currency: USD Updated: 2026-02-06

Key Insights

Repligen Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 190.62.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Repligen Corp's Score

Industry at a Glance

Industry Ranking

10 / 205

Overall Ranking

79 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Repligen Corp Highlights

StrengthsRisks

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 5096.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 63.65M shares, increasing 4.06% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 96.00 shares of this stock.

Analyst Rating

Based on 22 analysts

Buy

Current Rating

190.624

Target Price

+30.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Repligen Corp is 9.36, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 188.81M, representing a year-over-year increase of 21.91%, while its net profit experienced a year-over-year increase of 2379.97%.

Score

Industry at a Glance

Previous score

9.36

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.51

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.55

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Repligen Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Repligen Corp is 7.45, ranking 85 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 5096.06, which is 21.16% below the recent high of 6174.19 and 141.87% above the recent low of -2133.75.

Score

Industry at a Glance

Previous score

7.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Repligen Corp is 8.09, ranking 59 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 190.00, with a high of 220.00 and a low of 160.00.

Score

Industry at a Glance

Previous score

8.09

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 22 analysts

Buy

Current Rating

190.624

Target Price

+30.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Repligen Corp

RGEN

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Repligen Corp is 6.61, ranking 118 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 165.19 and the support level at 128.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-4.973

Sell

RSI(14)

30.285

Neutral

STOCH(KDJ)(9,3,3)

10.439

Oversold

ATR(14)

7.676

Low Volatility

CCI(14)

-121.091

Sell

Williams %R

89.919

Oversold

TRIX(12,20)

-0.405

Sell

StochRSI(14)

48.884

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

145.860

Sell

MA10

152.206

Sell

MA20

158.695

Sell

MA50

162.360

Sell

MA100

154.047

Sell

MA200

139.183

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Repligen Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 113.07%, representing a quarter-over-quarter increase of 15.24%. The largest institutional shareholder is The Vanguard, holding a total of 4.98M shares, representing 8.85% of shares outstanding, with 1.90% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.03M

-0.67%

BlackRock Institutional Trust Company, N.A.

4.64M

-1.50%

T. Rowe Price Associates, Inc.

Star Investors

3.46M

+0.81%

Roy T. Eddleman UEO

3.31M

-2.00%

United Capital Financial Advisors, LLC

2.76M

Fidelity Management & Research Company LLC

2.29M

+68.16%

State Street Investment Management (US)

1.80M

+11.03%

Citadel Advisors LLC

1.68M

+58.48%

Point72 Asset Management, L.P.

Star Investors

1.44M

-24.70%

Holocene Advisors, LP

1.38M

+47.00%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Repligen Corp is 7.37, ranking 42 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.